This study investigates the integrase sequence variability in Poland. The authors analysed integrase sequences in 80 treatment naive and experienced patients who never received integrase inhibitors. Thirty showed polymorphic variations previously described linked to integrase inhibitors but never major resistance mutations. Forty-six out of the 80 patients have later received RAL and twelve failing to the treatment were then analysed. They described 4 cases showing the appearance of major resistance mutations to INI. Results are not very new but the study is clear and the patients have been well studied.

Minor comments:
In the abstract: the sentence, lines 25-26 ("...plasma samples of 80 integrase treatment naive patients and raltegravir treatment failing subjects were analysed."), concerning the number of studied patients is confusing. They analysed 80 treatment naive patients and 12 raltegravir treatment failing subjects.

Some errors in the figure legends (line 502) have to be corrected: tenovir, emticitavbine

Explanations of abbreviations are missing in Table 1: IDU, MSM

**Level of interest:** An article of limited interest

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**
I declare that I have no competing interests